PCM
ENTA icon

Prelude Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Prelude Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-245
Closed -$11K – 1467
2020
Q3 		$11K Buy
245
+59
+32% +$2.86K ﹤0.01% 1440
2020
Q2 		$9K Hold
186
– – ﹤0.01% 1593
2020
Q1 		$10K Sell
186
-1,194
-87% -$63.6K ﹤0.01% 1127
2019
Q4 		$85K Buy
+1,380
New +$85.6K ﹤0.01% 1166
2018
Q4 		– Sell
-116
Closed -$10K – 1872
2018
Q3 		$10K Sell
116
-62
-35% -$6.21K ﹤0.01% 1454
2018
Q2 		$21K Buy
+178
New +$17.8K ﹤0.01% 1344
2018
Q1 		– Sell
-146
Closed -$9K – 1562
2017
Q4 		$9K Sell
146
-412
-74% -$20.6K ﹤0.01% 1212
2017
Q3 		$26K Sell
558
-146
-21% -$5.87K ﹤0.01% 1260
2017
Q2 		$25K Sell
704
-2,031
-74% -$65K ﹤0.01% 1208
2017
Q1 		$84K Sell
2,735
-3,267
-54% -$102K 0.01% 841
2016
Q4 		$201K Sell
6,002
-6,278
-51% -$180K 0.02% 581
2016
Q3 		$327K Buy
12,280
+5,455
+80% +$127K 0.03% 412
2016
Q2 		$150K Buy
6,825
+5,125
+301% +$134K 0.02% 593
2016
Q1 		$50K Buy
+1,700
New +$47.3K 0.01% 972
2015
Q3 		– Sell
-7,400
Closed -$333K – 1554
2015
Q2 		$333K Buy
7,400
+6,000
+429% +$233K 0.05% 423
2015
Q1 		$43K Sell
1,400
-2,100
-60% -$81.7K 0.01% 1379
2014
Q4 		$178K Sell
3,500
-720
-17% -$32.2K 0.03% 699
2014
Q3 		$167K Buy
+4,220
New +$168K 0.02% 785

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prelude Capital Management's ENTA Position: Q4 2020 in Review

Prelude Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 245 shares — an estimated $11K sold.

Prelude Capital Management first reported a position in ENTA in Q3 2014 and held it in 18 quarters. The position peaked at $333K in Q2 2015. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Prelude Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 245 Enanta Pharmaceuticals shares in Q4 2020, an estimated $11K.
  • Prelude Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 18 quarters.
  • Prelude Capital Management's Enanta Pharmaceuticals position peaked at $333K in Q2 2015.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.